About WPD Pharmaceuticals WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. WPD has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development. These drug candidates were researched at institutions including MD Anderson Cancer Center, Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.
has 8 novel drug candidates with 4 that are in clinical development stage and 4 in pre-clinical development.
4 präklinisch und 4 in der Entwicklung. Einer in Phase 1 /2 . d.h. hier werden wohl noch einige Gelder benötigt. Wäre die Entwicklung schon weiter, sagen wir mal Phase 2 und 3, würde ich sofort einsteigen. So abwarten, bis sich erstmal die Euphorie verzogen hat und mal schauen wie es aussieht.
"...Financial statements have been prepared assuming the Company will continue on a going concern basis: The financial statements have been prepared on the basis that the Company will continue as a going concern. The Company has not yet achieved profitable operations, has incurred significant operating losses and negative cash flows from operations, and has been reliant on external debt and equity financing. As at October 31, 2019, the Company has accumulated losses of $3,085,766. There is no assurance that the Company will be successful in generating and maintaining profitable operations or in securing future debt or equity financing for its working capital and development activities. Failure to continue as a going concern would require that the Company’s assets and liabilities be restated on a liquidation basis which would likely differ significantly from their going concern assumption carrying values..."
"...The Company will require additional equity financing to be raised in the future. The Company may issue securities on less than favourable terms to raise sufficient capital to fund its business plan. Any transaction involving the issuance of equity securities or securities convertible into common shares would result in dilution, possibly substantial, to present and prospective holders of common shares..."